BioVie Inc (NASDAQ:BIVI) said it will present an abstract showcasing baseline data from its Phase 3 study (NCT04669028) of NE3107 in patients with mild to moderate Alzheimer’s disease at the 83rd Scientific Sessions of the American Diabetes Association.
The event is scheduled for June 23-26 in San Diego, the company said.
The poster, titled “Metabolic Dysregulation in Probable Alzheimer’s Disease (Christopher Reading, et al),” discusses the role of insulin resistance and neuroinflammation in the risk of mild cognitive impairment and Alzheimer’s Disease, and details baseline metabolic and inflammation characteristics from the Phase 3 study, including data on the regulation of glycemia, the company said.
BioVie’s presentation is scheduled for 11:30 am on June 24.
Previously, the company’s Phase 2 study showed that NE3107 was associated with improvements in neurophysiological, neuropsychological, and biomarker status, and the treatment was associated with several patient and study partner-reported benefits, including improved mood and memory.
The company added that no adverse safety signal has been observed in any clinical study of NE3107.
BioVie is developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease.
Contact Andrew Kessel at andrew.kessel@proactiveinvestors.com
Follow him on Twitter @andrew_kessel